Clinical trial · Observational
Resection of Metastatic Pancreatic Neuroendocrine Tumors After Induction System Treatment
Resection of Metastatic Pancreatic Neuroendocrine Tumors After Induction System Treatment: Real World Study
NCT04066322CI-TRIAL-00040773RMPanNETunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is to evaluate the efficacy and tolerability of surgery in selecting patients who can benefit from the synchronous resection of primary pancreatic neuroendocrine tumor and liver metastasis after induction systemic treatment. The willing of participants decide who receive surgery and who will continue to receive standard systemic treatment.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastases | — | UNRESOLVED | — |
| Neuroendocrine Tumors | Neuroendocrine Tumor | ONTOLOGY_EXACT | 0.90 |
| Surgery | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| system treatment | Other | — | UNRESOLVED |
| system treatment and surgery | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- system treatment
- description
- Patients continue to receive standard system treatment, including SSA, targeted therapy and chemotherapy.
- interventionNames
- Other: system treatment
- label
- system treatment and Surgery
- description
- Patients receive synchronous resection of primary tumor and metastasis after system treatment. and treatment after surgery is based on the clinical decision.
- interventionNames
- Procedure: system treatment and surgery
Primary outcomes (1)
- measure
- progression-free survival
- timeFrame
- 5 years
Secondary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Biopsy-proven neuroendocrine tumor 2. primary site in pancreas 3. Advanced disease with lymph node or distant metastases (N1, M1) cannot undergoing cytoreduction by surgery/local ablative therapy at the diagnosis 4. curative intent of all therapies possible 5. ECOG 0-2 Exclusion Criteria: 1. Undifferentiated neuroendocrine carcinoma or mixed neuroendocrine carcinoma secondary tumor 2. functioning NET or advanced carcinoid heart disease 3. part of hereditary syndrome, such as MEN1, VHL 4. do not willing to receive systemic treatment 5. diagnosed with other cancer within 5 years
References
Publications (0)
Data not yet available
No reference posted for this study.